Firefly Neuroscience, Inc.

AI-generated fair value estimate for this company.

Method: Net asset value (book value) approach: $14.66M total shareholders' equity (predominantly $9.23M net cash, no debt) divided by 15.69M shares outstanding.

Reasoning: Firefly is a pre-commercial-scale medical device company with only $1.80M TTM revenue and a $9.44M net loss, making a cash-flow-based valuation premature; book value, mostly net cash, is the most defensible floor value until its FDA-cleared Evoke System reaches meaningful commercial adoption.